We are searching data for your request:
Upon completion, a link will appear to access the found materials.
11 million deaths occur each year in children under the age of 5 in the world, and the second most common cause is circle disease. In other words, diarrhea is gastoenteritis. The most common cause of gastroenteritis in the world is route virus. 29-45% of gastoenteritis causes 2 million deaths each year. In other words, the route virus causes 600 000 children to die each year and more than 2 million children fight hospital dehydration. The course of this disease can be quite harsh on prognosis and has variable results. It ends with different results in different countries. This disease, which can achieve complete remission with timely and early treatment, results in 80% death in backward countries such as South Asia and Africa.
1. What does the vaccine promise?
In the light of the studies, the World Health Organization (who) says that the best solution against this virus is the vaccine. Because;
? The vaccine strengthens the body's immune system (immune), providing protection against acquired rotavirus infection.
? Rota is the best solutions against virus spread; compliance with hygiene rules, protection of public health by vaccination, and fight against other diarrheal diseases and viruses through state health policies.
? Drugs to be administered intravenously, which are life-saving, are drugs that are based on the principle of replenishing the water lost in the body through diarrhea and will cause a very difficult hospital period for children. So this treatment is quite long, difficult, laborious and expensive.
? Vaccine is the best life-saving and virus-terminating solution in developed and developing countries.
2. New Route Virus Vaccine
These vaccines produced by 2 different companies, orally administered and developed against route virus, were approved in 2006 by the European Drug Administration and the United States Food and Drug Supervisory Board. The vaccine's protection against the route virus causing gastroenteritis has been demonstrated by clinical tests in Europe and America. Many developed and developing countries have approved this vaccine and added routine vaccination programs in their countries. Of course, this vaccine is routinely administered in many health institutions in our country.
These vaccines have been developed in developed countries but have started to be administered in different regions. Because the world health organization has granted privilege to Asia and Africa region, this vaccine has been started to be used rapidly by cooperating with various countries.
3. Developmental Stages of Rota Virus Vaccine
The first route virus vaccine was given in the United Nations in 1998. USA, Venazuella and Finland, the vaccine was started to be used in 80-100% of the effect, m was also understood that some of the side effects were not very serious.
However, in 1999, the vaccine was removed from the market because it caused intestinal obstruction and did not prevent the virus from entering the cell in one in every 12000 children.
Researchers have worked extensively with scientists, community health offices and vaccine manufacturers to discuss the benefit-harm balance of the route virus vaccine. As the discussions continued, child deaths, epidemics and hospitalized children continued.
Today's rotavirus vaccines are designed not to cause any increase in the risk of virus-infected cells. In other words, the studies that enabled us to come to today's level have produced vaccines that will not cause any confusion.
4. Criticisms of Vaccination
Research has shown that when a vaccine is available, it can take years for people who need it most to get it.
For example, the introduction of Hepatitis B and influenza vaccines in World 2 countries has shown a delay of 15-18 years compared to developed countries. Inadequate transport, undetermined requirements and high cost have led to the unfavorable spread of the drug. The reason for this problem in some countries is the lack of information about the severity and severity of the disease. The potential value of the vaccines could not be understood unless the necessary information was provided by the health institutions. To shorten the time between vaccine development and the applicability of the vaccine in developing countries, the route virus vaccine program is working in partnership with many healthcare organizations.